Clinical trials: Prostate
Prostatic Hyperplasia
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful waiting, with a defined escalation to tamsulosin…
- Trial name
- CONDUCT (NCT01294592)
- Testing
- Dutasteride plus tamsulosin, tamsulosin
- Where
- 80 sites in France, Germany and 6 more
- Volunteers
- 742 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
The purpose of the study is to evaluate procedure tolerability and surgical recovery following the UroLift® system procedure when conducted with local anesthesia in subjects with symptomatic benign hyperplasia (BPH).
- Trial name
- LOCAL (NCT01876706)
- Testing
- UroLift® System
- Where
- 7 sites in United States
- Volunteers
- 51 people
- Sponsor
- NeoTract, Inc.
Advanced Solid Tumours, Breast Cancer
A Study of IMP4297 in Patients With Advanced Solid Tumors
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03508011
- Testing
- IMP4297
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Impact Therapeutics, Inc.
Metastatic Castration-resistant Prostate Cancer
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer…
- Trial name
- NCT04740034
- Testing
- AMG 340
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Amgen
Prostate Cancer
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enrollment in this study was discontinued by the Sponsor on 01 Dec 2023.
- Trial name
- NCT05605964
- Testing
- Relugolix, Leuprolide Acetate
- Where
- 108 sites in United States
- Volunteers
- 387 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hormone-Refractory Prostate Cancer
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
This is a randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen-loaded dendritic cells (Provenge, APC8015) for asymptomatic, metastatic, hormone-refractory prostate cancer.
- Trial name
- NCT01133704
- Testing
- sipuleucel-T
- Volunteers
- 98 people
- Sponsor
- Dendreon
Prostate Cancer
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
The primary purpose of this study is to determine the effect of multiple once daily administrations of enzalutamide on the pharmacokinetics of a single dose of digoxin (P-glycoprotein (P-gp) substrate) and rosuvastatin (breast…
- Trial name
- NCT04094519
- Testing
- enzalutamide, digoxin, rosuvastatin
- Where
- Moldova
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Neoplasms
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
The primary objective of this trial is to estimate and compare the 12-week progression-free rate of BIBF 1120, BIBW 2992 or sequential administration of BIBF 1120 and BIBW 2992 in patients with HRPC as determined by radiographic…
- Trial name
- NCT00706628
- Testing
- BIBF 1120, BIBW 2992, Sequential BIBF 1120 + BIBW 2992
- Where
- 9 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia (BPH)
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
This clinical trial is designed as a randomized, placebo-controlled, single-blind, parallel design, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.
- Trial name
- NCT02855892
- Testing
- GV1001
- Where
- 8 sites in South Korea
- Volunteers
- 161 people
- Sponsor
- GemVax & Kael
Breast Cancer, Lung Cancer
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03662204
- Testing
- Blood Sample Collection
- Where
- 119 sites in United States
- Volunteers
- 5,133 people
- Sponsor
- Exact Sciences Corporation
Prostate Cancer
Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer
This study is intended to show that ExAblate™ MRgFUS is a safe procedure that can significantly postpone or eliminate the need of patients with organ confined intermediate risk prostate cancer to undergo a definitive treatment…
- Trial name
- NCT02968784
- Testing
- ExAblate MRgFUS
- Where
- 4 sites in Canada, China and 1 more
- Volunteers
- 53 people
- Sponsor
- InSightec
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related…
- Trial name
- NCT01332487
- Testing
- 5ARI + AB
- Volunteers
- 4,068 people
- Sponsor
- GlaxoSmithKline
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Bacterial Infections
BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis
The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of…
- Trial name
- NCT00670215
- Testing
- Ciprofloxacin single dose, Ciprofloxacin triple dose
- Where
- 51 sites in United States, Brazil and 4 more
- Volunteers
- 497 people
- Sponsor
- Bayer
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Ovarian Neoplasms, Breast Neoplasms
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01095848
- Testing
- DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Prostate Cancer
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy…
- Trial name
- ProComD (NCT02234089)
- Testing
- Degarelix, LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
- Where
- Germany
- Volunteers
- 461 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Study of Individualized Amonafide to Treat Prostate Cancer
The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted…
- Trial name
- NCT00087854
- Testing
- Amonafide L-malate (drug)
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Xanthus Pharmaceuticals, Inc.